Select your language
EN
FR
Home
About
About
Abionyx
Management
Board of Directors
Specialized Committees
- Audit Committee
- Remuneration Committee
Scientific Advisory Board
Our Assets
Our Assets
CER 001
CER 002
CER 209
Indications
LCAT
Sepsis
COVID
Media
Media
Press releases
ABIONYX in the media
Investors
Investors
Regulated information
Shareholder meeting
Analyst Research
Abionyx on stock market
Investor Contacts
Financial Calendar
Media
Press releases
ABIONYX in the media
Clinical results of the Phase 3 AEGIS-II study: - Validation of ABIONYX Pharma's strategic repositioning in severe diseases with short apoA-I treatment - No safety or tolerability problems in 18,000 patients
Fichier:
PR_Abionyx_021524_EN_d99d6.pdf